ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

ProQR Therapeutics (NASDAQ:PRQR) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.79 and traded as high as $3.69. ProQR Therapeutics shares last traded at $3.67, with a volume of 234,296 shares.

Analysts Set New Price Targets

Several equities analysts recently issued reports on PRQR shares. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. HC Wainwright increased their price target on ProQR Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Buy” and an average target price of $7.13.

ProQR Therapeutics Stock Up 0.3 %

The firm has a market cap of $295.68 million, a price-to-earnings ratio of -11.31 and a beta of 0.26. The company has a 50 day moving average of $2.86 and a 200 day moving average of $2.22.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its holdings in ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 19,100 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of ProQR Therapeutics during the 1st quarter valued at approximately $56,000. EP Wealth Advisors LLC bought a new position in ProQR Therapeutics during the first quarter worth $26,000. Ikarian Capital LLC boosted its holdings in ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock worth $1,098,000 after purchasing an additional 10,958 shares during the period. Finally, Privium Fund Management B.V. boosted its holdings in ProQR Therapeutics by 4.4% in the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock worth $9,208,000 after purchasing an additional 236,279 shares during the period. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).